Floatz logo

Veliparib

Thymic Carcinoid Tumor

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Thymic Carcinoid Tumor cohort.

Asset / SponsorPhaseRating
DOTATOC
Excel Diagnostics and Nuclear Oncology Center
Phase 2CCC
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 1CC
Bms-907351
National Cancer Institute (NCI)
Phase 3NR

Same molecule, other indications

Veliparib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Stage IV Pancreatic CancerDormant
BB
Indicative ·
71 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →